![Anti-PD-1 [5C4.B8 (Nivolumab)]](/skin/notimg.webp)
-
Anti-PD-1 [5C4.B8 (Nivolumab)]
Anti-PD-1 [5C4.B8 (Nivolumab)]
- 中文名称：
- Anti-PD-1 [5C4.B8 (Nivolumab)]
- 英文名称：
- Anti-PD-1 [5C4.B8 (Nivolumab)]
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA72299
- 规格：
- 0.2 mg|2x0.2 mg|3x0.2 mg|4x0.2 mg|5x0.2 mg
- 保存建议：
- Store at 4 degree C for up to 3 months. For longer storage, aliquot and store at -20 degree C.
- 货期：
- 6-8周
- 来源宿主：
- N/A
- 反应种属：
- Human, Cynomolgus
- 应用：
- Blocking, SPR (Surface Plasmon Resonance), FCM/FACS (Flow Cytometry), IHC (Immunohistochemistry)
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 其他：
克隆性:N/A
同型:Mouse IgG1 kappa
克隆号:[5C4.B8 (Nivolumab)]
特异性:Nivolumab binds to the extracellular portion of human PD-1 (2.6 nM - Scatchard analysis and SPR) - the antibody also binds to cynomolgus PD-1 with a similar affinity (3.9 nM - SPR). The antibody does not bind to other immunoglobulin superfamily proteins such as CD28, CTLA-4, ICOS and BTLA. The epitope of Nivolumab for both human and cynomolgus PD-1 includes the sequences SFVLNWYR-MSPSNQTDKLAAFPEDR (aa 29-53) and SGTYLCGAISLAPKAQIKE (aa 85-103), as shown by mass spectrometry of protease-treated fragments of PD-1 - these residues are thought to additionally be important for liand binding to PD-1. PD-1 is an inhibitory receptor expressed on the surface of T cells. It is able to bind to its ligands PDL-1 and PDL-2 which results in an inhibitory signal leading to decreased T cell proliferation, cytokine protuction and cytotoxic activtiy. PDL-1 is often expressed in human tumors such as melanoma, lung and kidney where it is able to overactivate PD-1 and plays a role in the evasion of cancer cells from the immune system.
纯度:Purified. Protein A affinity purified
形式：PBS with 0.02% Proclin 300.
浓度：1mg/ml
- 说明书：
mAb PD1.5 was prepared by immunizing IgH and IgK knock-out transgenic mice possessing a human immunoglobulin (heavy chain) minilocus with recombinant human PD-1-Fc protein consisting of the extracellular domain of PD-1 (amino acids 1-167) and the Fc portion of human IgG1, and Chinese hamster ovary (CHO) cells expressing human PD-1. Nivolumab was generated by grafting the variable regions of PD1.5 onto human kappa and IgG4 constant regions containing an S228P mutation (prevents Fab arm exchange with endogenous IgG4 antibodies).
Describes the generation and characterization of the anti-PD-1 antibody nivolumab, including its specicity, binding affinity and its in vivo and in vitro properties.
This chimeric mouse antibody was made using the variable domain sequences of the original human IgG4 (S228P) format, for improved compatibility with existing reagents, assays and techniques. NOT FOR THERAPEUTIC USE- This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques.
